These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33218823)

  • 1. Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.
    Iyer G; Bochner BH; Van Allen EM; Solit DB; Rosenberg JE
    Eur Urol; 2021 Feb; 79(2):e56-e57. PubMed ID: 33218823
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to Gopa Iyer, Bernard H. Bochner, Eliezer M. Van Allen, David B. Solit, and Jonathan E. Rosenberg's Letter to the Editor re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016.
    Becker REN; Baras A; Bivalacqua TJ
    Eur Urol; 2021 Feb; 79(2):e58-e59. PubMed ID: 33218822
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
    Van Allen EM; Garraway LA; Rosenberg JE
    Eur Urol; 2015 Aug; 68(2):e31-2. PubMed ID: 25770487
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Campodonico F; Mattioli F; Introini C
    Eur Urol; 2023 Feb; 83(2):e56-e57. PubMed ID: 36372625
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Sahoo S; Pandey A; Mandal S; Kumar Das M; Nayak P
    Eur Urol; 2023 Feb; 83(2):e47. PubMed ID: 36404203
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Kelly JD;
    Eur Urol; 2023 Jan; 83(1):e29-e30. PubMed ID: 36272948
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Eliezer M. Van Allen, Levi A. Garraway and Jonathan E. Rosenberg's Letter to the Editor re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014.
    Groenendijk FH; Fransen van de Putte EE; van Rhijn BW; Bernards R; van der Heijden MS
    Eur Urol; 2015 Aug; 68(2):e33-4. PubMed ID: 25776733
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Siobhan P. Lynch, Yu Shen, Ashish Kamat, et al. neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2012.04.020.
    Ismaili N
    Eur Urol; 2012 Sep; 62(3):e65-6. PubMed ID: 22682991
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
    Tan WS; Mustard C; Kelly JD;
    Eur Urol; 2023 Feb; 83(2):e48-e49. PubMed ID: 36456403
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036.
    Ayubi E; Safiri S
    Eur Urol; 2017 Dec; 72(6):e157. PubMed ID: 28576506
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033.
    Ghoreifi A; Djaladat H
    Eur Urol; 2020 Nov; 78(5):e184-e185. PubMed ID: 32951928
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Marc-Oliver Grimm, Antione G. van der Heijden, Marc Colombel, et al. Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS". Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.066.
    Karabay E; Tınay İ
    Eur Urol; 2020 Oct; 78(4):e161-e162. PubMed ID: 32682616
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.041.
    Orczyk C; Marsden T; Emberton M
    Eur Urol; 2021 Mar; 79(3):e98-e99. PubMed ID: 33341284
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Luca F. Valle, Eric J. Lehrer, Daniela Markovic, et al. A Systematic Review and Meta-analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.11.010.
    Kim SE; Shin JI; Shoag JE
    Eur Urol; 2021 Jul; 80(1):e14. PubMed ID: 33941402
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Stephen B. Williams, Marcus G.K. Cumberbatch, Ashish M. Kamat, et al. Reporting Radical Cystectomy Outcomes Following Implementation of Enhanced Recovery After Surgery Protocols: A Systematic Review and Individual Patient Data Meta-analysis. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.06.039.
    Giannarini G; Ficarra V; Valotto C
    Eur Urol; 2020 Nov; 78(5):e188-e189. PubMed ID: 32800725
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Yunjin Bai, Yubo Yang, and Yin Tang's Letter to the Editor re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. Eur Urol 2020;77:636-43. Eur Urol 2020;77:e158: Can mpMRI Replace Conventional Transurethral Resection of Bladder Cancer?
    Vila-Reyes H; DeCastro GJ; McKiernan JM
    Eur Urol; 2021 Jan; 79(1):e35-e36. PubMed ID: 32829975
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathon I. Epstein, et al. Active Surveillance of Grade Group 1 Prostate Cancer: Long-term Outcomes from a Large Prospective Cohort. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.017.
    Froehner M; Koch R; Thomas C
    Eur Urol; 2020 Aug; 78(2):e91. PubMed ID: 32381458
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
    Sjödahl G; Abrahamsson J; Holmsten K; Bernardo C; Eriksson P; Kollberg P; Marzouka NA; Höglund M; Ullén A; Liedberg F
    Eur Urol; 2022 Apr; 81(4):e92-e93. PubMed ID: 35039183
    [No Abstract]   [Full Text] [Related]  

  • 19. Reply to Erfan Ayubi and Saeid Safiri's Letter to the Editor re: R. Jeffrey Karnes, Voleak Choeurng, Ashley E. Ross, et al. Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2017.03.036. Methodological Issues.
    Trock BJ; Karnes RJ
    Eur Urol; 2017 Dec; 72(6):e158-e159. PubMed ID: 28576503
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
    Wei Y; Ye D; Zhu Y
    Eur Urol; 2022 Aug; 82(2):e51. PubMed ID: 35599186
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.